logo

Clearside Biomedical, Inc. (CLSD)



Trade CLSD now with
  Date
  Headline
3/20/2018 6:44:15 AM Wedbush Reiterates Clearside Biomedical, Inc. (CLSD) At Outperform With $29 Price Target
3/20/2018 6:43:01 AM Wedbush Is Increasing Clearside Biomedical, Inc. (CLSD) FY18 Estimate To -2.10 From -2.37
3/20/2018 6:42:33 AM Wedbush Is Increasing Clearside Biomedical, Inc. (CLSD) Q4 17 Estimate To -0.59 From -0.67
3/20/2018 6:42:00 AM Wedbush Is Raising Clearside Biomedical, Inc. (CLSD) Q3 18 Estimate To -0.51 From -0.57
3/20/2018 6:41:12 AM Wedbush Is Raising Clearside Biomedical, Inc. (CLSD) Q2 18 Estimate To -0.50 From -0.56
3/20/2018 6:40:53 AM Wedbush Is Increasing Clearside Biomedical, Inc. (CLSD) Q1 18 Estimate To -0.50 From -0.56
3/14/2018 7:11:36 AM Clearside Biomedical Q4 Net Loss $16.5 Mln Or $0.65/Shr Vs $9.7 Mln Or $0.45/Shr Last Year
3/5/2018 7:08:12 AM Clearside Announces Positive Topline Results From Pivotal Phase 3 Trial Of CLS-TA In Macular Edema Associated
2/26/2018 8:17:11 AM Clearside Biomedical Appoints William Humphries As Chairman And Brion Raymond As Chief Commercial Officer
12/6/2017 12:03:10 PM Wedbush Is Raising Clearside Biomedical, Inc. (CLSD) FY18 Estimate To -2.37 From -2.59
12/6/2017 12:02:36 PM Wedbush Is Increasing Clearside Biomedical, Inc. (CLSD) Q4 18 Estimate To -0.67 From -0.70
12/6/2017 12:02:13 PM Wedbush Is Increasing Clearside Biomedical, Inc. (CLSD) Q3 18 Estimate To -0.57 From -0.66
12/6/2017 12:01:51 PM Wedbush Is Raising Clearside Biomedical, Inc. (CLSD) Q2 18 Estimate To -0.56 From -0.63